SOURCE: Nutra Pharma Corporation

Nutra Pharma Corporation

August 19, 2010 09:03 ET

Nutra Pharma Begins Drug Registration Process in India for Nyloxin -- A Treatment for Moderate to Severe Chronic Pain

Nutra Pharma Has Begun the Drug Registration Process in India for Its Nyloxin Line of Pain Relievers; The Company Is Also Seeking a Relationship With an India-Based Pharmaceutical Company to Support the Launch, Marketing and Sales of Nyloxin Throughout India

CORAL SPRINGS, FL--(Marketwire - August 19, 2010) - Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, announced today that it has begun the drug registration process in India for its Nyloxin line of pain relievers.

According to a 1998 study published in the Journal of the American Medical Association (JAMA), it was estimated that 19% of patients evaluated in India suffered from persistent pain. An additional 2007 report from the Journal of Pain and Symptom Management, documented that only 0.4% of India's population in need of opioids for pain relief had access to them.

"India represents one of the more significant international market opportunities for Nyloxin," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "With the population of India exceeding a billion people and with limited patient access to opioid-based pain relievers throughout the country, India presents a potentially significant customer base for Nyloxin," he added.

Nyloxin, which was first introduced in November 2009 as a treatment for moderate to severe, Stage 2, chronic pain, is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.

"We are working diligently to complete all of the steps required to finalize this drug registration and move forward with launching Nyloxin in India," explained David Isserman, Chief Marketing Officer of Nutra Pharma Corporation. "Concurrently, we are seeking a relationship with a qualified India-based distributor that can offer both the financial resources and the local distribution and marketing knowledge required to successfully launch and support sales of Nyloxin throughout the country," he concluded.

About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Adrenomyeloneuropathy (AMN), Multiple Sclerosis (MS), and Human Immunodeficiency Virus (HIV). Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin and Nyloxin. For additional information about Nutra Pharma, visit:

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. Beginning the Nyloxin drug registration process in India or the drug registration itself, if approved, should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact Information

  • Contact:
    Nutra Pharma Corp.
    David Isserman
    Email Contact